Ocular Therapeutix reports a smaller-than-expected Q2 loss and revenue exceeding forecasts by $0.28M.
Ocular Therapeutix posted a Q2 GAAP loss of $0.35 per share, beating expectations by $0.04. Revenue reached $13.48M, surpassing estimates by $0.28M despite a 0.1% year-over-year decline.
The company’s total net revenue of $13.5 million remained flat compared to the same quarter in 2025. Analysts had anticipated a narrower loss but slightly lower revenue for the period.
Shares may react to the earnings beat, though the flat annual revenue growth could limit upside.